miR-200c regulates crizotinib-resistant ALK-positive lung cancer cells by reversing epithelial-mesenchymal transition via targeting ZEB1

Crizotinib is an orally administered drug for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). Despite the impressive efficacy of crizotinib in the treatment of ALK-positive lung cancer, acquired resistance ev...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Hai-Xiang, Yan, Li, Li, Chunzhi, Zhao, Lian-Mei, Liu, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2016
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5101903/
https://www.ncbi.nlm.nih.gov/pubmed/27666124
http://dx.doi.org/10.3892/mmr.2016.5770

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5101903/
https://www.ncbi.nlm.nih.gov/pubmed/27666124
http://dx.doi.org/10.3892/mmr.2016.5770

Ejemplares similares